AstraZeneca PLC (AstraZeneca) operates as a global pharmaceutical company.
The company engages in the research, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: (i) On…
Analysis
Middle-of-the-road
AstraZeneca PLC is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
The price is fair. You pay 22.4× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 8% yearly growth; analysts expect 12%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is adequate. The company scores 16/20 on our value-creation score: strong value creator.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202390
55
2023202420252026
All-time high
76
Mar 2026
All-time low
10
Nov 2024
Average rank
40
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
42
26
28
44
Price/Earnings
31
51
51
58
Price/Book
34
18
15
34
Dividend Yield
63
69
74
70
Value (overall)
43
37
44
31
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.